Interstitial Lung Disease | GCCNurseJobs Clinical Guide

🫁 What is Interstitial Lung Disease (ILD)?

Interstitial lung disease (ILD) is a heterogeneous group of over 200 diffuse parenchymal lung disorders characterised by inflammation and/or fibrosis of the lung parenchyma — the alveolar walls, perivascular tissue, and connective tissue framework. The result is progressive dyspnoea, restrictive lung function, and impaired gas exchange.

Key Concept: ILD causes a restrictive pattern on lung function testing — reduced FVC, reduced TLC, reduced DLCO (diffusion capacity). FEV1/FVC ratio is normal or elevated (unlike obstructive disease).

📋 Classification of ILD

Category	Examples	Key Features
Idiopathic Interstitial Pneumonias	IPF (most common), NSIP, COP, AIP	No identifiable cause; IPF worst prognosis
Hypersensitivity Pneumonitis	Bird fancier's lung, farmer's lung, hot tub lung	Antigen exposure → immune reaction
Connective Tissue Disease	RA-ILD, SSc-ILD, SLE-ILD, myositis-ILD	ILD can precede or follow CTD diagnosis
Drug-Induced ILD	Amiodarone, methotrexate, nitrofurantoin, bleomycin	Reversible if drug stopped early
Sarcoidosis	Multi-system granulomatous disease	Bilateral hilar lymphadenopathy + ILD
Occupational/Environmental	Asbestosis, silicosis, coal worker's pneumoconiosis	Occupational dust exposure; GCC relevance

🔬 Idiopathic Pulmonary Fibrosis (IPF) — Key Details

IPF is the most common and most severe ILD. It is a progressive fibrosing ILD of unknown cause, characterised by the histological and radiological pattern of Usual Interstitial Pneumonia (UIP).

Typical Patient Profile

Age >60 years
Male predominance
Smoker or ex-smoker
Progressive dyspnoea and dry cough
Bibasal fine late-inspiratory crackles — "Velcro crackles"
Digital clubbing (in approximately 50%)

Prognosis: IPF has a median survival of 3-5 years from diagnosis. It is progressive and irreversible. Antifibrotic drugs slow progression but do not reverse fibrosis. Lung transplantation is the only cure.

🔍 Clinical Assessment of ILD

History

Onset and progression of dyspnoea and cough
Occupational history — dust, asbestos, silica, birds, farming
Drug history — amiodarone, methotrexate, nitrofurantoin, bleomycin, checkpoint inhibitors
Connective tissue disease symptoms — joint pain, rash, Raynaud's, dry eyes/mouth
Smoking history
Family history of ILD
Bird exposure (hypersensitivity pneumonitis)

Examination

Respiratory rate and SpO₂ at rest and on exertion
Bibasal fine "Velcro" crackles on auscultation — characteristic of IPF/UIP
Digital clubbing
Signs of cor pulmonale — raised JVP, peripheral oedema, loud P2
Connective tissue disease signs — synovitis, sclerodactyly, Gottron's papules

🖥️ Investigations — Diagnosis

Gold Standard: High-Resolution CT (HRCT) of the chest is the gold standard for diagnosing ILD — NOT plain CXR. HRCT provides detailed parenchymal images that identify specific ILD patterns.

HRCT Patterns

Pattern	ILD Type	Characteristic Finding
UIP (Usual Interstitial Pneumonia)	IPF	Bibasal honeycomb cysts ± traction bronchiectasis; subpleural
NSIP (Non-Specific Interstitial Pneumonia)	CTD-ILD, drug-induced	Bibasal ground glass opacity (GGO); subpleural sparing
COP (Cryptogenic Organising Pneumonia)	Post-infection, drug-induced	Peripheral consolidation; "reversed halo sign"
Hypersensitivity Pneumonitis	Antigen exposure	Upper/mid GGO; mosaic attenuation; tree-in-bud
Sarcoidosis	Sarcoidosis	Bilateral hilar lymphadenopathy + peribronchovascular nodules

Additional Investigations

Pulmonary function tests (PFTs): restrictive pattern — reduced FVC, TLC, DLCO
6-Minute Walk Test (6MWT): standard functional capacity assessment; desaturation on exertion
Autoimmune screen: ANA, anti-dsDNA, RF, anti-CCP, anti-Scl70, anti-Jo-1
BAL (bronchoalveolar lavage): differential cell count; exclude infection
Surgical lung biopsy: when HRCT non-diagnostic

💊 Pharmacological Management

Pirfenidone (Esbriet)

Antifibrotic agent — mechanism: anti-fibrotic, anti-inflammatory, anti-oxidant effects. Slows FVC decline in IPF. Dose: 801 mg three times daily with food. Side effects: photosensitivity (avoid sun exposure), GI intolerance (nausea, dyspepsia), liver enzyme elevation. Monitor: LFTs at baseline, then monthly for first 6 months.

Nintedanib (Ofev)

Tyrosine kinase inhibitor — antifibrotic. Blocks PDGF, VEGF, FGF receptors involved in fibroblast activation. Slows FVC decline in IPF and some CTD-ILDs. Dose: 150 mg twice daily with food. Side effects: diarrhoea (most common — up to 62%), nausea, liver enzyme elevation. Monitor: LFTs. Contraindicated in moderate-severe hepatic impairment.

Critical Concept: Antifibrotic drugs (pirfenidone and nintedanib) SLOW disease progression — they do NOT reverse established fibrosis and do NOT improve FVC. Patients and families must be counselled that these drugs stabilise, not cure, IPF.

Only Cure: Lung transplantation (bilateral preferred) is the only treatment that can improve survival in IPF. Patients should be referred early to transplant centres before FVC drops below 50-60% predicted.

🌬️ Oxygen and Supportive Care

Oxygen therapy: Target SpO₂ ≥92%; prescribe LTOT if resting SpO₂ <88% or exercise desaturation
Ambulatory oxygen: For exertional desaturation during activities
Palliative opioids: Low-dose oral morphine for refractory dyspnoea — effective and evidence-based in end-stage ILD
Pulmonary rehabilitation: Improves exercise capacity and quality of life; does not alter disease progression
Vaccination: Annual influenza + pneumococcal vaccination to reduce exacerbation triggers
Advance care planning: Early discussion of goals of care given poor prognosis in IPF
Acid reflux treatment: Proton pump inhibitors — microaspiration is a proposed IPF trigger

6-Minute Walk Test (6MWT)

The 6MWT is the standard assessment of functional exercise capacity in ILD. The nurse measures the distance walked in 6 minutes on a flat 30-metre corridor. SpO₂ and HR are monitored before, during, and after. A drop in SpO₂ below 88% during 6MWT indicates the need for ambulatory oxygen.

🚨 Acute Exacerbation of IPF (AE-IPF)

AE-IPF is a life-threatening acute deterioration superimposed on the chronic course of IPF with no identifiable cause (after excluding infection, PE, pneumothorax, fluid overload).

Clinical Features

Rapid deterioration in dyspnoea over days to weeks
New bilateral GGO on HRCT superimposed on UIP background
Hypoxaemia requiring increased O₂ or mechanical ventilation

Management

Exclude infection (BAL, blood cultures), PE (CTPA), and heart failure
High-dose corticosteroids (methylprednisolone IV) — often used empirically despite limited evidence
Supportive oxygen; consider NIV
Mechanical ventilation: generally poor outcome in AE-IPF; shared decision-making essential

Prognosis of AE-IPF: In-hospital mortality 50-80%. Surviving patients have accelerated progression thereafter. Early palliative care involvement is essential.

⚠️ Complications of ILD / IPF

Complication	Mechanism	Management
Pulmonary Hypertension	Chronic hypoxia → vasoconstriction; fibrosis destroys vasculature	Supplemental O₂; consider specific PH therapy
Cor Pulmonale	Right heart failure secondary to pulmonary hypertension	Diuretics; O₂; transplant consideration
Acute Exacerbation	Unknown trigger; new inflammation on fibrotic background	Steroids; supportive care; palliative care
Lung Cancer	Increased risk in smokers with IPF (common antecedents)	CT surveillance; resection if operable
Respiratory Failure	Progressive fibrosis → impaired gas exchange	LTOT; NIV; end-of-life care planning

💊 Drug-Induced ILD — Key Drugs to Know

Drug	ILD Pattern	Reversibility
Amiodarone	NSIP-like/OP pattern; can be fatal	Partially reversible with drug cessation; may need steroids
Methotrexate	Hypersensitivity pneumonitis-like	Usually reversible with cessation
Nitrofurantoin	Acute/chronic HP-like pattern	Acute form reversible; chronic may persist
Bleomycin	NSIP/UIP-like; dose-dependent	Partially reversible; O₂ worsens bleomycin toxicity
Checkpoint Inhibitors (immunotherapy)	Any pattern; pneumonitis	Usually steroid-responsive

Nursing Vigilance: When a patient on amiodarone, methotrexate, or nitrofurantoin develops new dyspnoea or cough, always consider drug-induced ILD. Report to the medical team promptly. Drug cessation is the first management step.

🌍 GCC-Specific Context

Desert Dust Pneumonitis — Hypersensitivity Pneumonitis in GCC ▼

The GCC region is characterised by high ambient dust levels from desert environments. Fine particulate matter from desert dust (haboobs and chronic low-level dust exposure) can cause hypersensitivity pneumonitis-like reactions and exacerbate pre-existing ILD. Patients presenting with ILD in the GCC should be asked specifically about: proximity to desert areas, outdoor exposure during dusty seasons, occupational dust exposure (construction, agriculture), and symptom correlation with sandstorm events. This is termed "desert dust pneumonitis" in some literature.

Haboob (Sandstorm) as Acute Exacerbation Trigger ▼

Haboobs — large desert sandstorms common in Saudi Arabia, UAE, Oman, Kuwait, and Qatar — cause massive spikes in PM10 and PM2.5 particulate levels. In patients with established ILD (especially IPF and hypersensitivity pneumonitis), haboob exposure can trigger acute exacerbations. GCC nurses should counsel ILD patients to: (1) Stay indoors during sandstorm events; (2) Use N95 masks if outdoor exposure cannot be avoided; (3) Ensure emergency oxygen supply is accessible at home; (4) Have an action plan for acute dyspnoea during dust events. This is a culturally and environmentally specific consideration unique to GCC nursing practice.

Occupational ILD in GCC Construction Workers ▼

GCC countries — particularly UAE, Qatar, and Saudi Arabia — have undergone massive construction booms. Migrant construction workers from South Asia, Southeast Asia, and Africa constitute a large proportion of the workforce and are at risk of silicosis (crystalline silica from concrete/sandblasting), asbestosis (older buildings containing asbestos), and other pneumoconioses. GCC nurses working in occupational health, pulmonology, or emergency departments should be aware of: (1) High-risk occupational groups; (2) Long latency periods for silicosis (10-30 years); (3) Regulatory frameworks — UAE Federal Authority for Government Human Resources (FAHR) and Qatar Labour Law mandating occupational health screening.

ILD Nursing Management in GCC Clinical Settings ▼

IPF and ILD management in GCC hospitals is typically managed by specialist pulmonologists. Nursing roles include: (1) Oxygen therapy monitoring — SpO₂ targets ≥92% at rest; (2) 6-minute walk test coordination and monitoring; (3) Antifibrotic drug education (pirfenidone photosensitivity counselling; nintedanib diarrhoea management); (4) Pulmonary rehabilitation programme support; (5) Advance care planning and end-of-life discussions in keeping with Islamic bioethical principles; (6) Coordinating home oxygen equipment in GCC home care services. Language barriers are significant in GCC — nursing education materials should be available in Arabic, Urdu, Tagalog, and Malayalam for the diverse patient population.

🎯 High-Yield Exam Points

ILD = restrictive lung disease pattern (reduced FVC, TLC, DLCO)
Most common ILD with worst prognosis: IPF
IPF classic findings: Velcro crackles, clubbing, male >60, smoker
Gold standard diagnosis: HRCT chest (not CXR)
UIP pattern on HRCT: honeycombing ± traction bronchiectasis, bibasal subpleural
Antifibrotics: pirfenidone and nintedanib — slow progression, do NOT reverse fibrosis
Only cure for IPF: lung transplantation
Functional assessment: 6-minute walk test
Oxygen target in ILD: SpO₂ ≥92%
Dyspnoea palliation: low-dose opioids (morphine) — evidence-based
Drug-induced ILD: amiodarone, methotrexate, nitrofurantoin, bleomycin
AE-IPF prognosis: 50-80% in-hospital mortality
GCC: sandstorm (haboob) = acute exacerbation risk in ILD patients

❓ Practice MCQs

1. A 67-year-old male ex-smoker presents with a 2-year history of progressive exertional dyspnoea and dry cough. Auscultation reveals fine bibasal late-inspiratory crackles. Which investigation is MOST appropriate for establishing the diagnosis?

Correct answer: B — HRCT is the gold standard for diagnosing ILD. It identifies the specific ILD pattern (e.g., UIP/honeycombing in IPF) with high accuracy. Plain CXR is insensitive and non-specific. Spirometry shows restriction but does not diagnose the ILD subtype.

2. A patient with IPF is prescribed pirfenidone. Which side effect requires specific patient education before commencing this medication?

Correct answer: C — Pirfenidone causes photosensitivity (sun-sensitive rash) — patients must use SPF 50+ sunscreen, wear protective clothing, and minimise sun exposure. GI side effects (nausea) are common too, but photosensitivity is the most distinctive and important counselling point. Nintedanib causes diarrhoea; pirfenidone causes photosensitivity.

3. A nurse is conducting a 6-minute walk test (6MWT) on a patient with IPF. During the test, the patient's SpO₂ drops from 94% to 85%. The nurse's PRIORITY action is to:

Correct answer: B — SpO₂ below 88% during exertion is a safety threshold requiring immediate oxygen and test cessation. This result also indicates the need for ambulatory oxygen prescription. Safety always takes priority over completing the test.

4. A patient with IPF asks the nurse whether the prescribed nintedanib will "cure" their condition. The nurse's BEST response is:

Correct answer: C — This answer correctly describes the mechanism and realistic expectations of antifibrotic therapy. Nintedanib (and pirfenidone) slow the rate of FVC decline but do not reverse established fibrosis. Honest, compassionate communication about this is essential for informed consent and realistic hope. Lung transplantation remains the only cure.